Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Silke Gillessen; Andrew Armstrong; Gert Attard; Tomasz M Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Robert G Bristow; Muhammad Bulbul; Orazio Caffo; Kim N Chi; Caroline S Clarke; Noel Clarke; Ian D Davis; Johann S de Bono; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Jason Efstathiou; Onyeanunam Ngozi Ekeke; Christopher P Evans; Stefano Fanti; Felix Y Feng; Karim Fizazi; Mark Frydenberg; Dan George; Martin Gleave; Susan Halabi; Daniel Heinrich; Celesta Higano; Michael S Hofman; Maha Hussain; Nick James; Robert Jones; Ravindran Kanesvaran; Raja B Khauli; Laurence Klotz; Raya Leibowitz; Chris Logothetis; Fernando Maluf; Robin Millman; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Hind Mrabti; Declan G Murphy; Vedang Murthy; William K Oh; Piet Ost; Joe M O'Sullivan; Anwar R Padhani; Chris Parker; Darren M C Poon; Colin C Pritchard; Danny M Rabah; Dana Rathkopf; Rob E Reiter; Mark Rubin; Charles J Ryan; Fred Saad; Juan P Sade; Oliver Sartor; Howard I Scher; Neal Shore; Iwona Skoneczna; Eric Small; Matthew Smith; Howard Soule; Daniel E Spratt; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Mary-Ellen Taplin; Derya Tilki; Bertrand Tombal; Levent Türkeri; Hiroji Uemura; Hirotsugu Uemura; Inge van Oort; Kosj Yamoah; Dingwei Ye; Almudena Zapatero; Aurelius Omlin

doi:10.1016/j.eururo.2022.04.002

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Standard

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. / Gillessen, Silke; Armstrong, Andrew; Attard, Gert; Beer, Tomasz M; Beltran, Himisha; Bjartell, Anders; Bossi, Alberto; Briganti, Alberto; Bristow, Robert G; Bulbul, Muhammad; Caffo, Orazio; Chi, Kim N; Clarke, Caroline S; Clarke, Noel; Davis, Ian D; de Bono, Johann S; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Ekeke, Onyeanunam Ngozi; Evans, Christopher P; Fanti, Stefano; Feng, Felix Y; Fizazi, Karim; Frydenberg, Mark; George, Dan; Gleave, Martin; Halabi, Susan; Heinrich, Daniel; Higano, Celesta; Hofman, Michael S; Hussain, Maha; James, Nick; Jones, Robert; Kanesvaran, Ravindran; Khauli, Raja B; Klotz, Laurence; Leibowitz, Raya; Logothetis, Chris; Maluf, Fernando; Millman, Robin; Morgans, Alicia K; Morris, Michael J; Mottet, Nicolas; Mrabti, Hind; Murphy, Declan G; Murthy, Vedang; Oh, William K; Ost, Piet; O'Sullivan, Joe M; Padhani, Anwar R; Parker, Chris; Poon, Darren M C; Pritchard, Colin C; Rabah, Danny M; Rathkopf, Dana; Reiter, Rob E; Rubin, Mark; Ryan, Charles J; Saad, Fred; Sade, Juan P; Sartor, Oliver; Scher, Howard I; Shore, Neal; Skoneczna, Iwona; Small, Eric; Smith, Matthew; Soule, Howard; Spratt, Daniel E; Sternberg, Cora N; Suzuki, Hiroyoshi; Sweeney, Christopher; Sydes, Matthew R; Taplin, Mary-Ellen; Tilki, Derya; Tombal, Bertrand; Türkeri, Levent; Uemura, Hiroji; Uemura, Hirotsugu; van Oort, Inge; Yamoah, Kosj; Ye, Dingwei; Zapatero, Almudena; Omlin, Aurelius.

In: EUR UROL, Vol. 82, No. 1, 07.2022, p. 115-141.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gillessen, S, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, CS, Clarke, N, Davis, ID, de Bono, JS, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ekeke, ON, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, HI, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, DE, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, MR, Taplin, M-E, Tilki, D, Tombal, B, Türkeri, L, Uemura, H, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A & Omlin, A 2022, 'Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021', EUR UROL, vol. 82, no. 1, pp. 115-141. https://doi.org/10.1016/j.eururo.2022.04.002

APA

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., Caffo, O., Chi, K. N., Clarke, C. S., Clarke, N., Davis, I. D., de Bono, J. S., Duran, I., Eeles, R., Efstathiou, E., ... Omlin, A. (2022). Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. EUR UROL, 82(1), 115-141. https://doi.org/10.1016/j.eururo.2022.04.002

Vancouver

Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. EUR UROL. 2022 Jul;82(1):115-141. https://doi.org/10.1016/j.eururo.2022.04.002

Bibtex

@article{5ef95d2930e248268339d2a44e65d005,

title = "Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021",

abstract = "BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence.OBJECTIVE: To present the voting results from APCCC 2021.DESIGN, SETTING, AND PARTICIPANTS: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process.RESULTS AND LIMITATIONS: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material.CONCLUSIONS: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials.PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making.",

keywords = "Consensus, Humans, Male, Prostatic Neoplasms/diagnosis",

author = "Silke Gillessen and Andrew Armstrong and Gert Attard and Beer, {Tomasz M} and Himisha Beltran and Anders Bjartell and Alberto Bossi and Alberto Briganti and Bristow, {Robert G} and Muhammad Bulbul and Orazio Caffo and Chi, {Kim N} and Clarke, {Caroline S} and Noel Clarke and Davis, {Ian D} and {de Bono}, {Johann S} and Ignacio Duran and Ros Eeles and Eleni Efstathiou and Jason Efstathiou and Ekeke, {Onyeanunam Ngozi} and Evans, {Christopher P} and Stefano Fanti and Feng, {Felix Y} and Karim Fizazi and Mark Frydenberg and Dan George and Martin Gleave and Susan Halabi and Daniel Heinrich and Celesta Higano and Hofman, {Michael S} and Maha Hussain and Nick James and Robert Jones and Ravindran Kanesvaran and Khauli, {Raja B} and Laurence Klotz and Raya Leibowitz and Chris Logothetis and Fernando Maluf and Robin Millman and Morgans, {Alicia K} and Morris, {Michael J} and Nicolas Mottet and Hind Mrabti and Murphy, {Declan G} and Vedang Murthy and Oh, {William K} and Piet Ost and O'Sullivan, {Joe M} and Padhani, {Anwar R} and Chris Parker and Poon, {Darren M C} and Pritchard, {Colin C} and Rabah, {Danny M} and Dana Rathkopf and Reiter, {Rob E} and Mark Rubin and Ryan, {Charles J} and Fred Saad and Sade, {Juan P} and Oliver Sartor and Scher, {Howard I} and Neal Shore and Iwona Skoneczna and Eric Small and Matthew Smith and Howard Soule and Spratt, {Daniel E} and Sternberg, {Cora N} and Hiroyoshi Suzuki and Christopher Sweeney and Sydes, {Matthew R} and Mary-Ellen Taplin and Derya Tilki and Bertrand Tombal and Levent T{\"u}rkeri and Hiroji Uemura and Hirotsugu Uemura and {van Oort}, Inge and Kosj Yamoah and Dingwei Ye and Almudena Zapatero and Aurelius Omlin",

year = "2022",

month = jul,

doi = "10.1016/j.eururo.2022.04.002",

language = "English",

volume = "82",

pages = "115--141",

journal = "EUR UROL",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

RIS

TY - JOUR

T1 - Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

AU - Gillessen, Silke

AU - Armstrong, Andrew

AU - Attard, Gert

AU - Beer, Tomasz M

AU - Beltran, Himisha

AU - Bjartell, Anders

AU - Bossi, Alberto

AU - Briganti, Alberto

AU - Bristow, Robert G

AU - Bulbul, Muhammad

AU - Caffo, Orazio

AU - Chi, Kim N

AU - Clarke, Caroline S

AU - Clarke, Noel

AU - Davis, Ian D

AU - de Bono, Johann S

AU - Duran, Ignacio

AU - Eeles, Ros

AU - Efstathiou, Eleni

AU - Efstathiou, Jason

AU - Ekeke, Onyeanunam Ngozi

AU - Evans, Christopher P

AU - Fanti, Stefano

AU - Feng, Felix Y

AU - Fizazi, Karim

AU - Frydenberg, Mark

AU - George, Dan

AU - Gleave, Martin

AU - Halabi, Susan

AU - Heinrich, Daniel

AU - Higano, Celesta

AU - Hofman, Michael S

AU - Hussain, Maha

AU - James, Nick

AU - Jones, Robert

AU - Kanesvaran, Ravindran

AU - Khauli, Raja B

AU - Klotz, Laurence

AU - Leibowitz, Raya

AU - Logothetis, Chris

AU - Maluf, Fernando

AU - Millman, Robin

AU - Morgans, Alicia K

AU - Morris, Michael J

AU - Mottet, Nicolas

AU - Mrabti, Hind

AU - Murphy, Declan G

AU - Murthy, Vedang

AU - Oh, William K

AU - Ost, Piet

AU - O'Sullivan, Joe M

AU - Padhani, Anwar R

AU - Parker, Chris

AU - Poon, Darren M C

AU - Pritchard, Colin C

AU - Rabah, Danny M

AU - Rathkopf, Dana

AU - Reiter, Rob E

AU - Rubin, Mark

AU - Ryan, Charles J

AU - Saad, Fred

AU - Sade, Juan P

AU - Sartor, Oliver

AU - Scher, Howard I

AU - Shore, Neal

AU - Skoneczna, Iwona

AU - Small, Eric

AU - Smith, Matthew

AU - Soule, Howard

AU - Spratt, Daniel E

AU - Sternberg, Cora N

AU - Suzuki, Hiroyoshi

AU - Sweeney, Christopher

AU - Sydes, Matthew R

AU - Taplin, Mary-Ellen

AU - Tilki, Derya

AU - Tombal, Bertrand

AU - Türkeri, Levent

AU - Uemura, Hiroji

AU - Uemura, Hirotsugu

AU - van Oort, Inge

AU - Yamoah, Kosj

AU - Ye, Dingwei

AU - Zapatero, Almudena

AU - Omlin, Aurelius

PY - 2022/7

Y1 - 2022/7

N2 - BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence.OBJECTIVE: To present the voting results from APCCC 2021.DESIGN, SETTING, AND PARTICIPANTS: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process.RESULTS AND LIMITATIONS: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material.CONCLUSIONS: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials.PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making.

AB - BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence.OBJECTIVE: To present the voting results from APCCC 2021.DESIGN, SETTING, AND PARTICIPANTS: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process.RESULTS AND LIMITATIONS: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material.CONCLUSIONS: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials.PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making.

KW - Consensus

KW - Humans

KW - Male

KW - Prostatic Neoplasms/diagnosis

U2 - 10.1016/j.eururo.2022.04.002

DO - 10.1016/j.eururo.2022.04.002

M3 - SCORING: Journal article

C2 - 35450732

VL - 82

SP - 115

EP - 141

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 1

ER -